About

Dan Levine has advised clients in strategic and financial transactions, principally involving China, for more than 17 years. He focuses his practice on inbound and…

Dan Levine has advised clients in strategic and financial transactions, principally involving China, for more than 17 years. He focuses his practice on inbound and outbound M&A, joint ventures, private equity and venture capital investments, and technology licensing transactions.

Dan provides strategic and transactional advice to Chinese and Western clients navigating critical political, legal, and regulatory hurdles to their international strategies—including national security reviews conducted by the Committee on Foreign Investment in the United States (CFIUS), China’s outbound investment review process, the U.S.’s proposed outbound investment screening regime, China’s overseas listing rules, and export controls.

Dan has extensive experience in the clean energy, life sciences, and technology sectors. In recent years this has included:

  • counseling leading global electric vehicle battery and energy storage companies with respect to incentive programs under the Bipartisan Infrastructure Law and Inflation Reduction Act;
  • advising a leading global medical device company in a joint venture with a Chinese state-owned entity to develop and commercialize imaging equipment in China; and
  • advising a Chinese gene therapy company in a complex pre-IPO outbound acquisition.

Dan’s pro bono work includes representing U.S. health care professionals and Chinese companies to procure and supply personal protective equipment from China to the United States during the COVID-19 pandemic.

Dan reads, writes, and speaks Mandarin and has lived in China for extended periods since 2001, including when resident in Covington’s Shanghai office from 2013-2022.

About

Dan Levine has advised clients in strategic and financial transactions, principally involving China, for more than 17 years. He focuses his practice on inbound and…

Dan Levine has advised clients in strategic and financial transactions, principally involving China, for more than 17 years. He focuses his practice on inbound and outbound M&A, joint ventures, private equity and venture capital investments, and technology licensing transactions.

Dan provides strategic and transactional advice to Chinese and Western clients navigating critical political, legal, and regulatory hurdles to their international strategies—including national security reviews conducted by the Committee on Foreign Investment in the United States (CFIUS), China’s outbound investment review process, the U.S.’s proposed outbound investment screening regime, China’s overseas listing rules, and export controls.

Dan has extensive experience in the clean energy, life sciences, and technology sectors. In recent years this has included:

  • counseling leading global electric vehicle battery and energy storage companies with respect to incentive programs under the Bipartisan Infrastructure Law and Inflation Reduction Act;
  • advising a leading global medical device company in a joint venture with a Chinese state-owned entity to develop and commercialize imaging equipment in China; and
  • advising a Chinese gene therapy company in a complex pre-IPO outbound acquisition.

Dan’s pro bono work includes representing U.S. health care professionals and Chinese companies to procure and supply personal protective equipment from China to the United States during the COVID-19 pandemic.

Dan reads, writes, and speaks Mandarin and has lived in China for extended periods since 2001, including when resident in Covington’s Shanghai office from 2013-2022.

Subscribe: Subscribe via RSS